Related references
Note: Only part of the references are listed.Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer
Shumei Kato et al.
INVESTIGATIONAL NEW DRUGS (2018)
Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis
Changki Lee et al.
CANCER LETTERS (2018)
Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer
Jeeyun Lee et al.
CLINICAL COLORECTAL CANCER (2018)
Primary central nervous system histiocytic sarcoma A case report and review of literature
Shuang Ma et al.
MEDICINE (2018)
Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment
M. Fioramonti et al.
SCIENTIFIC REPORTS (2018)
A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification
Eric Angevin et al.
EUROPEAN JOURNAL OF CANCER (2017)
Cabozantinib improves clinical outcomes in renal cancer
Manjulika Das
LANCET ONCOLOGY (2017)
A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)
James I. Geller et al.
PEDIATRIC BLOOD & CANCER (2017)
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer
Kohei Shitara et al.
ONCOTARGET (2017)
Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions
Marco Fioramonti et al.
ONCOTARGET (2017)
Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone
Kai-Jie Yu et al.
ONCOTARGET (2017)
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer
Stephen K. Chia et al.
BREAST CANCER RESEARCH (2017)
MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation
Tom T. Chen et al.
EBIOMEDICINE (2015)
Potent antitumor activity of cabozantinib, a c- MET and VEGFR2 inhibitor, in a colorectal cancer patient- derived tumor explant model
Eun-Kee Song et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions
Jinlu Dai et al.
CLINICAL CANCER RESEARCH (2014)
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
Holly M. Nguyen et al.
PLOS ONE (2013)
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Kan V. Lu et al.
CANCER CELL (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Evolving Role of Bone Biomarkers in Castration-Resistant Prostate Cancer
Janet E. Brown et al.
NEOPLASIA (2010)
Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases
Stephen Claridge et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid
Allan Lipton et al.
CANCER (2008)
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
RE Coleman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
HI Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Angiogenesis and lung cancer: Prognostic and therapeutic implications
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
JE Brown et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Hepatocyte growth factor, its receptor, and their potential value in cancer therapies
WG Jiang et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells
G Davies et al.
PROSTATE (2004)
Bone imaging in metastatic breast cancer
T Hamaoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
Share Paper
